Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors

BACKGROUND: Assessment of the status of tumor biomarkers in individual patients would facilitate personalizing treatment strategy, and continuous monitoring of those biomarkers and their binding process to the therapeutic drugs would provide a means for early evaluation of the efficacy of therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardeshirpour, Yasaman, Sackett, Dan L., Knutson, Jay R., Gandjbakhche, Amir H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884746/
https://www.ncbi.nlm.nih.gov/pubmed/29619584
http://dx.doi.org/10.1186/s13550-018-0384-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884746/
https://www.ncbi.nlm.nih.gov/pubmed/29619584
http://dx.doi.org/10.1186/s13550-018-0384-6

Ejemplares similares